Oric Pharmaceuticals, Inc. ORIC Net unrealized gains (losses) on securities still held
Net unrealized gains (losses) on securities still held at other companies
Other financials
Where this comes from
Reported directly by Oric Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax.
The official record: Oric Pharmaceuticals, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Oric Pharmaceuticals, Inc.'s net unrealized gains (losses) on securities still held.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Oric Pharmaceuticals, Inc.'s net unrealized gains (losses) on securities still held?
- Oric Pharmaceuticals, Inc. (ORIC) reported net unrealized gains (losses) on securities still held of -$1.08M in Q1 2026.
- How has Oric Pharmaceuticals, Inc.'s net unrealized gains (losses) on securities still held changed year-over-year?
- Oric Pharmaceuticals, Inc.'s net unrealized gains (losses) on securities still held decreased by 532.9% year-over-year, from -$170K to -$1.08M.
- What is the long-term trend for Oric Pharmaceuticals, Inc.'s net unrealized gains (losses) on securities still held?
- Over 2 years (2021 to 2025), Oric Pharmaceuticals, Inc.'s net unrealized gains (losses) on securities still held has grown at a 137.8% compound annual growth rate (CAGR), from -$72K to $407K.
- What does net unrealized gains (losses) on securities still held mean?
- This metric represents the change in the fair value of investment securities held by the company that have not yet been sold. It captures unrealized gains or losses that are excluded from net income but are recognized within equity as part of comprehensive income. Monitoring this figure provides insight into the volatility and performance of the company's investment portfolio outside of core operational activities.